Emerging drugs for treating skeletal muscle injury and promoting muscle repair

Expert Opinion on Emerging Drugs

Volumn 16, Issue 1, 2011, Pages 163-182

  Gehrig, Stefan M ^a   Lynch, Gordon S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

anabolic agents; fibrosis; growth factors; inflammation; muscle damage; muscle regeneration

Indexed keywords

ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ADHEREX; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BL 1040; BRX 220; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CORTICORELIN ACETATE; CORTICOTROPIN RELEASING FACTOR; CP 368296; CVT 3; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; ECULIZUMAB; EMRICASAN; ETANERCEPT; FLT3 LIGAND; GERMALL 115; GT 015; INGLIFORIB; KAI 9803; MIDKINE; NONSTEROID ANTIINFLAMMATORY AGENT; PCM 4; PLACEBO; RECOMBINANT SOMATOMEDIN C; REVASCOR; SDZ MTH 958; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VGX 3200; XERAGEN; XERECEPT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOL LIVER DISEASE; ANEMIA; BRAIN EDEMA; CACHEXIA; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DACHEXIA; DIABETES MELLITUS; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; ENTERITIS; GENE THERAPY; GRAFT VERSUS HOST REACTION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIA; ISCHEMIC HEART DISEASE; LUNG FIBROSIS; MEMBRANOUS GLOMERULONEPHRITIS; MULTIPLE SCLEROSIS; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE REGENERATION; MUSCULOSKELETAL INJURY; MYASTHENIA GRAVIS; NERVE INJURY; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PERIPHERAL VASCULAR DISEASE; REPERFUSION INJURY; RESTENOSIS; REVIEW; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; SPINAL CORD INJURY; THROMBOCYTE RICH PLASMA; TRAUMATIC BRAIN INJURY; TRAUMATIC SHOCK;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2 INHIBITORS; DRUG DISCOVERY; HUMANS; MUSCLE, SKELETAL; MUSCULAR DISEASES; REGENERATION; TREATMENT OUTCOME;

EID: 79952137538     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2010.524743     Document Type: Review

References (212)

1. Huard J, Li Y, Fu FH. Muscle injuries and repair: current trends in research. J Bone Joint Surg 2002;84A:822-32 (Pubitemid 34925047) (Pubitemid 34925047)
2. Lynch GS, Schertzer JD, Ryall JG. Anabolic agents for improving muscle regeneration and function after injury. Clin Exp Pharmacol Physiol 2008;16:852-8 (Pubitemid 351725245) (Pubitemid 351725245)
3. Proske U, Morgan DL, Brockett CL, et al. Identifying athletes at risk of hamstring strains and how to protect them. Clin Exp Pharmacol Physiol 2004;31:46-50
4. Barrie KA, Steinmann SP, Shin AY, et al. Gracilis free muscle transfer for restoration of function after complete brachial plexus avulsion. Neurosurg Focus 2004;16:E8
5. Schoeller T, Wechselberger G, Hussl H, et al. Functional transposition of the latissimus dorsi muscle for biceps reconstruction after upper arm replantation. J Plast Reconstr Aesthet Surg 2007;60:755-9 (Pubitemid 46852233) (Pubitemid 46852233)
6. Lien SC, Cederna PS, Kuzon WM Jr. Optimizing skeletal muscle reinnervation with nerve transfer. Hand Clin 2008;24:445-54
7. Choudhury NA, Sakaguchi S, Koyano K, et al. Free radical injury in skeletal muscle ischemia and reperfusion. J Surg Res 1991;51:392-8
8. Petrasek PF, Homer-Vanniasinkam S, Walker PM. Determinants of ischemic injury to skeletal muscle. J Vasc Surg 1994;19:623-31 (Pubitemid 24137117) (Pubitemid 24137117)
9. Lazarus B, Messina A, Barker JE, et al. The role of mast cells in ischaemia-reperfusion injury in murine skeletal muscle. J Pathol 2000;191:443-8 (Pubitemid 30649914) (Pubitemid 30649914)
10. Tupling R, Green H, Senisterra G, et al. Effects of 4-h ischemia and 1-h reperfusion on rat muscle sarcoplasmic reticulum function. Am J Physiol Endocrinol Metab 2001;281:E867-77
11. Blaisdell FW. The pathophysiology of skeletal muscle ischemia and the reperfusion syndrome: a review. Cardiovasc Surg 2002;10:620-30 (Pubitemid 35365880) (Pubitemid 35365880)
12. Carvalho AJ, McKee NH, Green HJ. Metabolic and contractile responses of fast and slow twitch rat skeletal muscles to ischemia and reperfusion. Plast Reconstr Surg 1997;99:163-71 (Pubitemid 27020734) (Pubitemid 27020734)
13. Mikos AG, Herring SW, Ochareon P, et al. Engineering complex tissues. Tissue Eng 2006;12:3307-39 (Pubitemid 46037158) (Pubitemid 46037158)
14. Pedowitz RA. Tourniquet-induced neuromuscular injury. A recent review of rabbit and clinical experiments. Acta Orthop Scand Suppl 1991;245:1-33
15. Eastlack RK, Groppo ER, Hargens AR, et al. Ischemic-preconditioning does not prevent neuromuscular dysfunction after ischemia-reperfusion injury. J Orthop Res 2004;22:918-23 (Pubitemid 38756278) (Pubitemid 38756278)
16. Hammers DW, Merritt EK, Matheny W, et al. Functional deficits and insulin-like growth factor-I gene expression following tourniquet-induced injury of skeletal muscle in young and old rats. J Appl Physiol 2008;105:1274-81
17. Sato K, Li Y, Foster W, et al. Improvement of muscle healing through enhancement of regeneration and prevention of fibrosis. Muscle Nerve 2003;28:365-72 (Pubitemid 37025346) (Pubitemid 37025346)
18. Li Y, Foster W, Deasy BM, et al. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am J Pathol 2004;164:1007-19 (Pubitemid 38235482) (Pubitemid 38235482)
19. Plant DR, Colarossi FE, Lynch GS. Notexin causes greater myotoxic damage and slower functional repair in mouse skeletal muscles than bupivacaine. Muscle Nerve 2006;34:577-85 (Pubitemid 44656080) (Pubitemid 44656080)
20. Carlson BM, Faulkner JA. The regeneration of skeletal muscle fibers following injury: a review. Med Sci Sports Exerc 1983;15:187-98. (Pubitemid 13010547) (Pubitemid 13010547)
21. Grounds MD. Towards understanding muscle regeneration. Pathol Res Pract 1991;187:1-22
22. Grounds MD. Muscle regeneration: molecular aspects and therapeutic implications. Curr Opin Neurol 1999;12:535-43 (Pubitemid 30028613) (Pubitemid 30028613)
23. Hawke TJ, Garry DJ. Myogenic satellite cells: physiology to molecular biology. J Appl Physiol 2001;91:534-51 (Pubitemid 32681081) (Pubitemid 32681081)
24. Charge SP, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004;84:209-38 (Pubitemid 38049880) (Pubitemid 38049880)
25. Tidball JG. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 2005;288:R345-53 (Pubitemid 40129595) (Pubitemid 40129595)
26. Beiner JM, Jokl P. Muscle contusion injuries: current treatment options. J Am Acad Orthop Surg 2001;9:227-37
27. Jarvinen TA, Jarvinen TL, Kaariainen M, et al. Muscle injuries: optimising recovery. Best Pract Res Clin Rheumatol 2007;21:317-31 (Pubitemid 46746637) (Pubitemid 46746637)
28. Cutlip RG, Baker BA, Hollander M, et al. Injury and adaptive mechanisms in skeletal muscle. J Electromyogr Kinesiol 2009;19:358-72
29. Heiderscheit BC, Sherry MA, Silder A, et al. Hamstring strain injuries: recommendations for diagnosis, rehabilitation, and injury prevention. J Orthop Sports Phys Ther 2010;40:67-81
30. Dennis RG, Kosnik PE II. Excitability and isometric contractile properties of mammalian skeletal muscle constructs engineered in vitro. In Vitro Cell Dev Biol Anim 2000;36:327-35 (Pubitemid 30619599) (Pubitemid 30619599)
31. Fodor WL. Tissue engineering and cell based therapies, from the bench to the clinic: the potential to replace, repair and regenerate. Reprod Biol Endocrinol 2003;1:102
32. Bach AD, Arkudas A, Tjiawi J, et al. A new approach to tissue engineering of vascularized skeletal muscle. J Cell Mol Med 2006;10:716-26 (Pubitemid 44874280) (Pubitemid 44874280)
33. Corsi KA, Schwarz EM, Mooney DJ, Huard J. Regenerative medicine in orthopaedic surgery. J Orthop Res 2007;25:1261-8 (Pubitemid 47523355) (Pubitemid 47523355)
34. Pacak CA, Cowan DB. Fabrication of myogenic engineered tissue constructs. J Vis Exp 2009;27pii:1137
35. Atala A. Advances in tissue and organ replacement. Curr Stem Cell Res Ther 2008;3(1):21-31 (Pubitemid 352024864) (Pubitemid 352024864)
36. Stern-Straeter J, Bach AD, Stangenberg L, et al. Impact of electrical stimulation on three-dimensional myoblast cultures - A real-time RT-PCR study. J Cell Mol Med 2005;9:883-92 (Pubitemid 43116553) (Pubitemid 43116553)
37. Freed LE, Guilak F, Guo XE, et al. Advanced tools for tissue engineering: scaffolds, bioreactors, and signaling. Tissue Eng 2006;12:3285-305 (Pubitemid 46037157) (Pubitemid 46037157)
38. Hutmacher DW, Cool S. Concepts of scaffold-based tissue engineering-The rationale to use solid free-form fabrication techniques. J Cell Mol Med 2007;11:654-69 (Pubitemid 47315712) (Pubitemid 47315712)
39. Sherry MA, Best TM. A comparison of 2 rehabilitation programs in the treatment of acute hamstring strains. J Orthop Sports Phys Ther 2004;34:116-25 (Pubitemid 38392029) (Pubitemid 38392029)
40. Guillodo Y, Saraux A. Treatment of muscle trauma in sportspeople (from injury on the field to resumption of the sport). Ann Phys Rehabil Med 2009;52:246-55
41. Moore RA, Derry S, Phillips CJ, McQuay HJ. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006;7:79
42. Buenaventura RM, Datta S, Abdi S, Smith HS. Systematic review of therapeutic lumbar transforaminal epidural steroid injections. Pain Physician 2009;12:233-51
43. Massey T, Derry S, Moore RA, et al. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev 2010;6:CD007402
44. Ziltener JL, Leal S, Fournier PE. Non-steroidal anti-inflammatory drugs for athletes: an update. Ann Physical Rehabil Med 2010;53:278-82
45. Thorsson O, Rantanen J, Hurme T, et al. Effects of nonsteroidal anti-inflammatory medication on satellite cell proliferation during muscle regeneration. Am J Sports Med 1998;26:172-6 (Pubitemid 28157970) (Pubitemid 28157970)
46. Wright-Carpenter T, Klein P, Schaferhoff P, et al. Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. Int J Sports Med 2004;25:588-93 (Pubitemid 39518136) (Pubitemid 39518136)
47. Dreyer HC, Blanco CE, Sattler FR, et al. Satellite cell numbers in young and older men 24 hours after eccentric exercise. Muscle Nerve 2006;33:242-53 (Pubitemid 43208681) (Pubitemid 43208681)
48. Mackey AL, Kjaer M, Dandanell S, et al. The influence of anti-inflammatory medication on exercise-induced myogenic precursor cell responses in humans. J Appl Physiol 2007;103:425-31 (Pubitemid 47204959) (Pubitemid 47204959)
49. Mikkelsen UR, Langberg H, Helmark IC, et al. Local NSAID infusion inhibits satellite cell proliferation in human skeletal muscle after eccentric exercise. J Appl Physiol 2009;107:1600-11
50. Spiro AS, Beil FT, Baranowsky A, et al. BMP-7-induced ectopic bone formation and fracture healing is impaired by systemic NSAID application in C57BL/6-mice. J Orthop Res 2010;28:785-91
51. Novak ML, Billich W, Smith SM, et al. COX-2 inhibitor reduces skeletal muscle hypertrophy in mice. Am J Physiol Regul Integr Comp Physiol 2009;296:R1132-9
52. Burd NA, Dickinson JM, Lemoine JK, et al. Effect of a cyclooxygenase-2 inhibitor on postexercise muscle protein synthesis in humans. Am J Physiol Endocrinol Metab 2010;298:E354-61
53. Cohen DB, Kawamura S, Ehteshami JR, Rodeo SA. Indomethacin and celecoxib impair rotator cuff tendon-to-bone healing. Am J Sports Med 2006;34:362-9 (Pubitemid 43260571) (Pubitemid 43260571)
54. Dimmen S, Nordsletten L, Engebretsen L, et al. Negative effect of parecoxib on bone mineral during fracture healing in rats. Acta Orthop 2008;79:438-44 (Pubitemid 352009343) (Pubitemid 352009343)
55. Boursinos LA, Karachalios T, Poultsides L, Malizos KN. Do steroids, conventional non-steroidal anti-inflammatory drugs and selective Cox-2 inhibitors adversely affect fracture healing? J Musculoskelet Neuronal Interact 2009;9:44-52
56. Paoloni JA, Orchard JW. The use of therapeutic medications for soft-tissue injuries in sports medicine. Med J Aust 2005;183:384-8 (Pubitemid 41430843) (Pubitemid 41430843)
57. Mehallo CJ, Drezner JA, Bytomski JR. Practical management: nonsteroidal antiinflammatory drug (NSAID) use in athletic injuries. Clin J Sports Med 2006;16:170-4 (Pubitemid 43670381) (Pubitemid 43670381)
58. Feucht CL, Patel DR. Analgesics and anti-inflammatory medications in sports: use and abuse. Pediatr Clin North Am 2010;57:751-74
59. Warden SJ. Cyclo-oxygenase-2 inhibitors: beneficial or detrimental for athletes with acute musculoskeletal injuries? Sports Med 2005;35:271-83
60. Warden SJ. Prophylactic use of NSAIDs by athletes: a risk/benefit assessment. Phys Sportsmed 2010;38:132-8
61. Jones P, Lamdin R. Oral cyclo-oxygenase 2 inhibitors versus other oral analgesics for acute soft tissue injury: systematic review and meta-analysis. Clin Drug Investig 2010;30:419-37
62. Garcia Rodriguez LA, Gonzalez-Perez A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Medicine 2005;3:17
63. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006;98:266-74
64. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44 (Pubitemid 44511610) (Pubitemid 44511610)
65. Singh G, Wu O, Langhorne P, et al. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Arthritis Res Ther 2006;8:R153
66. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009;2:155-63
67. Mowlavi A, Ghavami A, Song YH, Neumeister M. Limited use of cyclosporin A in skeletal muscle ischemia - reperfusion injury. Ann Plast Surg 2001;46:426-30 (Pubitemid 32319683) (Pubitemid 32319683)
68. Askar I, Bozkurt M. Protective effects of immunosuppressants and steroids against ischemia-reperfusion injury in cremaster muscle flap at microcirculatory level. Microsurgery 2002;22:361-6 (Pubitemid 36055802) (Pubitemid 36055802)
69. Chunasuwankul R, Ayrout C, Dereli Z, et al. Low dose discontinued FK506 treatment enhances peripheral nerve regeneration. Int Surg 2002;87:274-8
70. Udina E, Gold BG, Navarro X. Comparison of continuous and discontinuous FK506 administration on autograft or allograft repair of sciatic nerve resection. Muscle Nerve 2004;29:812-22 (Pubitemid 38720818) (Pubitemid 38720818)
71. Chabas JF, Alluin O, Rao G, et al. FK506 induces changes in muscle properties and promotes metabosensitive nerve fiber regeneration. J Neurotrauma 2009;26:97-108
72. Zbreski MG, Helwig BG, Mitchell KE, et al. Effects of cyclosporine-A on rat soleus muscle fiber size and phenotype. Med Sci Sports Exerc 2006;38:833-9
73. Aydin MA, Urbanchek MG, Kuzon WM. Improved early muscle recovery using FK506 in a rat nerve-repair model. J Reconstr Microsurg 2004;20:183-92 (Pubitemid 38264012) (Pubitemid 38264012)
74. Sakuma K, Nakao R, Aoi W, et al. Cyclosporin A treatment upregulates Id1 and Smad3 expression and delays skeletal muscle regeneration. Acta Neuropathol 2005;110:269-80 (Pubitemid 41430656) (Pubitemid 41430656)
75. Murphy KT, Ryall JG, Snell SM, et al. Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice. Am J Pathol 2010;176:2425-34
76. Murphy KT, Koopman R, Naim T, et al. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB J. 2010; In press
77. Lynch GS, Schertzer JD, Ryall JG. Therapeutic approaches for muscle wasting disorders. Pharmacol Ther 2007;113:461-87 (Pubitemid 46365957) (Pubitemid 46365957)
78. Lynch GS, Ryall JG. Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev 2008;88:729-67 (Pubitemid 351520091) (Pubitemid 351520091)
79. Lynch GS. Update on emerging drugs for sarcopenia - age-related muscle wasting. Expert Opin Emerg Drugs 2008;13:655-73.
80. Ryall JG, Lynch GS. The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting. Pharmacol Ther 2008;120:219-32
81. Koopman R, Ryall JG, Church JE, Lynch GS. The role of beta-adrenoceptor signaling in skeletal muscle: therapeutic implications for muscle wasting disorders. Curr Opin Clin Nutr Metab Care 2009;12:601-6
82. Murphy KT, Lynch GS. Update on emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 2009;14:619-32
83. Ryall JG, Church JE, Lynch GS. Novel role for beta-adrenergic signalling in skeletal muscle growth, development and regeneration. Clin Exp Pharmacol Physiol 2010;37:397-401
84. Harmon KG. Muscle injuries and PRP: what does the science say? Br J Sports Med 2010;44:616-17
85. Mei-Dan O, Mann G, Maffulli N. Platelet-rich plasma: any substance into it? Br J Sports Med 2010;44:618-19
86. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 2004;114:1502-8 (Pubitemid 40361959) (Pubitemid 40361959)
87. Mehta S, Watson JT. Platelet rich concentrate: basic science and current clinical applications. J Orthop Trauma 2008;22:432-8
88. Lopez-Vidriero E, Goulding KA, Simon DA, et al. The use of platelet-rich plasma in arthroscopy and sports medicine: optimizing the healing environment. Arthroscopy 2010;26:269-78
89. Hall MP, Band PA, Meislin RJ, et al. Platelet-rich plasma: current concepts and application in sports medicine. J Am Acad Orthop Surg 2009;17:602-8
90. Sanchez M, Anitua E, Orive G, et al. Platelet-rich therapies in the treatment of orthopaedic sport injuries. Sports Med 2009;39:345-54
91. Hammond JW, Hinton RY, Curl LA, et al. Use of autologous platelet-rich plasma to treat muscle strain injuries. Am J Sports Med 2009;37:1135-42
92. Mishra A, Woodall J Jr, Vieira A. Treatment of tendon and muscle using platelet-rich plasma. Clin Sports Med 2009;28:113-25
93. Obremsky WT, Seaber AV, Ribbeck BM, et al. Biomechanical and histologic assessment of a controlled muscle strain injury treated with piroxicam. Am J Sports Med 1994;22:558-61 (Pubitemid 24225763) (Pubitemid 24225763)
94. Wright-Carpenter T, Opolon P, Appell HJ, et al. Treatment of muscle injuries by local administration of autologous conditioned serum: animal experiments using a muscle contusion model. Int J Sports Med 2004;25:582-7 (Pubitemid 39518135) (Pubitemid 39518135)
95. Mock C, Cherian MN. The global burden of musculoskeletal injuries: challenges and solutions. Clin Orthop Relat Res 466:2306-16
96. United States Bone and Joint Decade. The burden of musculoskeletal diseases in the United States. Rosemont, IL. 2008; American Academy of Orthopaedic Surgeons. Available from: www.boneandjointburden.org for updates
97. Bevan S, Quadrello T, McGee R, et al. Fit for work? Musculoskeletal disorders in the European workforce. 2009; The Work Foundation, London. Available from: www.theworkfoundation.com for updates
98. Wagers AJ, Conboy IM. Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis. Cell 2005;122:659-67 (Pubitemid 41242632) (Pubitemid 41242632)
99. Toumi H, F'guyer S, Best TM. The role of neutrophils in injury and repair following muscle stretch. J Anat 2006;208:459-70
100. Smith C, Kruger MJ, Smith RM, et al. The inflammatory response to skeletal muscle injury: illuminating complexities. Sports Med 2008;38:947-69
101. Karalaki M, Fili S, Philippou A, et al. Muscle regeneration: cellular and molecular events. In Vivo 2009;23:779-96
102. Ghaly A, Marsh DR. Ischaemia-reperfusion modulates inflammation and fibrosis of skeletal muscle after contusion injury. Int J Exp Pathol 2010;91:244-55
103. Tidball JG. Inflammatory cell response to acute muscle injury. Med Sci Sports Exerc 1995;27:1022-32
104. Davis J. Eculizumab. Am J Health Syst Pharm 2008;65:1609-15
105. Robak E, Robak T. Monoclonal antibodies in the treatment of systemic lupus erythematosus. Curr Drug Targets 2009;10:26-37
106. Zareba KM. Eculizumab: a novel therapy for paroxysmal nocturnal hemoglobinuria. Drugs Today 2007;43:539-46 (Pubitemid 47529737) (Pubitemid 47529737)
107. Charneski L, Patel PN. Eculizumab in paroxysmal nocturnal haemoglobinuria. Drugs 2008;68:1341-6 (Pubitemid 351913432) (Pubitemid 351913432)
108. Zhou Y, Gong B, Lin F, et al. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol 2007;179:8562-7
109. Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008;131:1197-208
110. Moliterno JA, Henry E, Pannullo SC. Corticorelin acetate injections for the treatment of peritumoral brain edema. Expert Opin Investig Drugs 2009;18:1413-19
111. [No authors listed] Corticorelin: ACTH RF, corticoliberin, corticotrophin-releasing hormone, corticotropin-releasing factor, human corticotropin-releasing hormone, ovine corticotrophin-releasing factor, Xerecept. Drugs R D 2004;5:218-19
112. Reimann J, Schnell S, Schwartz S, et al. Macrophage migration inhibitory factor in normal human skeletal muscle and inflammatory myopathies. J Neuropathol Exp Neurol 2010;69:654-62
113. Supinski GS, Ji X, Wang W, et al. The extrinsic caspase pathway modulates endotoxin-induced diaphragm contractile dysfunction. J Appl Physiol 2007;102:1649-57 (Pubitemid 46571063) (Pubitemid 46571063)
114. Supinski GS, Ji X, Callahan LA. The JNK MAP kinase pathway contributes to the development of endotoxin-induced diaphragm caspase activation. Am J Physiol Regul Integr Comp Physiol 2009;297:R825-34
115. Supinski GS, Ji XY, Callahan LA. p38 Mitogen-activated protein kinase modulates endotoxin-induced diaphragm caspase activation. Am J Respir Cell Mol Biol 2010;43:121-7
116. Koseki T, Inohara N, Chen S, Nunez G. ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. Proc Natl Acad Sci USA 1998;95:5156-60 (Pubitemid 28208567) (Pubitemid 28208567)
117. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79
118. Choi DE, Jeong JY, Lim BJ, et al. Pretreatment with the tumor nerosis factor-alpha blocker etanercept attenuated ischemia-reperfusion renal injury. Transplant Proc 2009;41:3590-6
119. Esposito E, Cuzzocrea S. TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr Med Chem 2009;16:3152-67
120. Assasi N, Blackhouse G, Xie F, et al. Patient outcomes after anti TNF-alpha drugs for Crohn's disease. Expert Rev Pharmacoecon Outcomes Res 2010;10:163-75
121. Bachmann F, Nast A, Sterry W, et al. Safety and efficacy of the tumor necrosis factor antagonists. Semin Cutan Med Surg 2010;29:35-47
122. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976-86
123. Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010;30:339-53
124. Zador E, Mendler L, Takacs V, et al. Regenerating soleus and extensor digitorum longus muscles of the rat show elevated levels of TNF-alpha and its receptors, TNFR-60 and TNFR-80. Muscle Nerve 2001;24:1058-67 (Pubitemid 32656192) (Pubitemid 32656192)
125. Peterson JM, Feeback KD, Baas JH, et al. Tumor necrosis factor-alpha promotes the accumulation of neutrophils and macrophages in skeletal muscle. J Appl Physiol 2006;101:1394-9
126. Chen SE, Jin B, Li YP. TNF-alpha regulates myogenesis and muscle regeneration by activating p38 MAPK. Am J Physiol Cell Physiol 2007;292:C1660-71 (Pubitemid 47080547) (Pubitemid 47080547)
127. Musaro A, Giacinti C, Pelosi L, et al. Stem cell-mediated muscle regeneration and repair in aging and neuromuscular diseases. Eur J Histochem 2007;51(Suppl 1):35-43
128. Moresi V, Pristera A, Scicchitano BM, et al. Tumor necrosis factor-alpha inhibition of skeletal muscle regeneration is mediated by a caspase-dependent stem cell response. Stem Cells 2008;26:997-1008
129. Moresi V, Garcia-Alvarez G, Pristera A, et al. Modulation of caspase activity regulates skeletal muscle regeneration and function in response to vasopressin and tumor necrosis factor. PLoS One 2009;4:e5570
130. Gierer P, Rother J, Mittlmeier T, et al. Ebselen reduces inflammation and microvascular perfusion failure after blunt skeletal muscle injury of the rat. J Trauma 2010;68:853-8
131. Grounds MD, Davies M, Torrisi J, et al. Silencing TNFalpha activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice. Cell Tissue Res 2005;320:509-15 (Pubitemid 40884152) (Pubitemid 40884152)
132. Hodgetts S, Radley H, Davies M, et al. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscul Disord 2006;16:591-602 (Pubitemid 44374323) (Pubitemid 44374323)
133. Grounds MD, Torrisi J. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 2004;18:676-82 (Pubitemid 38451789) (Pubitemid 38451789)
134. Radley HG, Davies MJ, Grounds MD. Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment. Neuromuscul Disord 2008;18:227-38
135. Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: Forty-eight cases reported to the food and drug administration. Arthritis Rheum 2010;62:2517-24
136. Di Napoli M, Papa F. NCX-4016 NicOx. Curr Opin Investig Drugs 2003;4:1126-39 (Pubitemid 37321409) (Pubitemid 37321409)
137. Siddique A, Butt M, Shantsila E, et al. New antiplatelet drugs: beyond aspirin and clopidogrel. Int J Clin Pract 2009;63:776-89
138. Emanueli C, Van Linthout S, Salis MB, et al. Nitric oxide-releasing aspirin derivative, NCX 4016, promotes reparative angiogenesis and prevents apoptosis and oxidative stress in a mouse model of peripheral ischemia. Arterioscler Thromb Vasc Biol 2004;24:2082-7 (Pubitemid 39482434) (Pubitemid 39482434)
139. Gresele P, Momi S. Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc Drug Rev 2006;24:148-68 (Pubitemid 46696922) (Pubitemid 46696922)
140. Kurthy M, Mogyorosi T, Nagy K, et al. Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models. Ann NY Acad Sci 2002;967:482-9 (Pubitemid 34721936) (Pubitemid 34721936)
141. Kalmar B, Greensmith L, Malcangio M, et al. The effect of treatment with BRX-220, a co-inducer of heat shock proteins, on sensory fibers of the rat following peripheral nerve injury. Exp Neurol 2003;184:636-47 (Pubitemid 38182793) (Pubitemid 38182793)
142. Traynor BJ, Bruijn L, Conwit R, et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 2006;67:20-7 (Pubitemid 44305456) (Pubitemid 44305456)
143. Lanka V, Wieland S, Barber J, et al. Arimoclomol: a potential therapy under development for ALS. Expert Opin Investig Drugs 2009;18:1907-18
144. Phukan J. Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs 2010;13:482-96
145. Kieran D, Kalmar B, Dick JR, et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10:402-5 (Pubitemid 38508519) (Pubitemid 38508519)
146. Kalmar B, Novoselov S, Gray A, et al. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J Neurochem 2008;107:339-50
147. Kandzari DE, Dery JP, Armstrong PW, et al. MC-1 (pyridoxal 5c-phosphate): novel therapeutic applications to reduce ischaemic injury. Expert Opin Investig Drugs 2005;14:1435-42 (Pubitemid 41601457) (Pubitemid 41601457)
148. MEND-CABG II Investigators, Alexander JH, Emery RW Jr, et al. Efficacy and safety of pyridoxal 5c-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial. JAMA 2008;299:1777-87 (Pubitemid 351549969) (Pubitemid 351549969)
149. Carrier M, Emery R, Kandzari DE, et al. Protective effect of pyridoxal-5-phosphate (MC-1) on perioperative myocardial infarction is independent of aortic cross clamp time: results from the MEND-CABG trial. J Cardiovasc Surg 2008;49:249-53 (Pubitemid 351833246) (Pubitemid 351833246)
150. Dube GP, Vranckx P, Greenburg AG. HBOC-201: the multi-purpose oxygen therapeutic. EuroIntervention 2008;4:161-5
151. Greenburg AG. The ideal blood substitute. Crit Care Clin 2009;25:415-24
152. Chen JY, Scerbo M, Kramer G. A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers. Clinics 2009;64:803-13
153. Donahue LL, Shapira I, Shander A, et al. Management of acute anemia in a Jehovah's Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature. Transfusion 2010;50:1561-7
154. Yonezawa T, Kurata R, Kimura M, Inoko H. PKC delta and epsilon in drug targeting and therapeutics. Recent Pat DNA Gene Seq 2009;3:96-101
155. Bates E, Bode C, et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 2008;117:886-96 (Pubitemid 351272586) (Pubitemid 351272586)
156. Han R, Bakker AJ. The effect of chelerythrine on depolarization-induced force responses in skinned fast skeletal muscle fibres of the rat. Br J Pharmacol 2003;138:417-26 (Pubitemid 36269482) (Pubitemid 36269482)
157. Wei W, Wei FC, Hung LM. Diazoxide ameliorates microcirculatory disturbances through PKC-dependent pathway in I/R-injured rat cremaster muscles. J Biomed Sci 2005;12:521-9 (Pubitemid 41032315) (Pubitemid 41032315)
158. Lin JY, Hung LM, Lai LY, et al. Kappa-opioid receptor agonist protects the microcirculation of skeletal muscle from ischemia reperfusion injury. Ann Plast Surg 2008; 61:330-6
159. Tracey WR, Treadway JL, Magee WP, et al. Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor. Am J Physiol Heart Circ Physiol 2004;286:H1177-84 (Pubitemid 38248635) (Pubitemid 38248635)
160. Baker DJ, Greenhaff PL, MacInnes A, et al. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction. Diabetes 2006;55:1855-61
161. Landa N, Miller L, Feinberg MS, et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation 2008;117:1388-96 (Pubitemid 351506386) (Pubitemid 351506386)
162. Leor J, Tuvia S, Guetta V, et al. Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine. J Am Coll Cardiol 2009;54:1014-23
163. Tsur-Gang O, Ruvinov E, Landa N, et al. The effects of peptide-based modification of alginate on left ventricular remodeling and function after myocardial infarction. Biomaterials 2009;30:189-95
164. Barton ER. The ABCs of IGF-I isoforms: impact on muscle hypertrophy and implications for repair. Appl Physiol Nutr Metab 2006;31:791-7
165. Ambrosio F, Kadi F, Lexell J, et al. The effect of muscle loading on skeletal muscle regenerative potential: an update of current research findings relating to aging and neuromuscular pathology. Am J Phys Med Rehabil 2009;88:145-55
166. Frystyk J. Exercise and the growth hormone-insulin-like growth factor axis. Med Sci Sports Exerc 2010;42:58-66
167. Matheny RW Jr, Nindl BC, Adamo ML. Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology 2010;151:865-75
168. Lynch GS. Emerging drugs for sarcopenia: age-related muscle wasting. Expert Opin Emerg Drugs 2004;9:345-61 (Pubitemid 39627135) (Pubitemid 39627135)
169. Engert JC, Berglund EB, Rosenthal N. Proliferation precedes differentiation in IGF-I-stimulated myogenesis. J Cell Biol 1996;135:431-40 (Pubitemid 26359336) (Pubitemid 26359336)
170. Musaro A, McCullagh K, Paul A, et al. Localized Igf-1 transgene
171. Barton ER, Morris L, Musaro A, et al. Muscle specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 2002;157:137-48
172. Shavlakadze T, White J, Hoh JF, et al. Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice. Mol Ther 2004;10:829-43 (Pubitemid 39419910) (Pubitemid 39419910)
173. Schertzer JD, van der Poel C, Shavlakadze T, et al. Muscle-specific overexpression of IGF-I improves E-C coupling in skeletal muscle fibers from dystrophic mdx mice. Am J Physiol Cell Physiol 2008;294:C161-8
174. Schertzer JD, Lynch GS. Comparative evaluation of IGF-I gene transfer and IGF-I protein administration for enhancing skeletal muscle regeneration after injury. Gene Ther 2006;13:1657-64 (Pubitemid 44774210) (Pubitemid 44774210)
175. Schertzer JD, Ryall JG, Lynch GS. Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice. Am J Physiol Endocrinol Metab 2006;291:E499-505 (Pubitemid 44352255) (Pubitemid 44352255)
176. Schertzer JD, Gehrig SM, Ryall JG, et al. Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice. Am J Pathol 2007;171:1180-8 (Pubitemid 47582892) (Pubitemid 47582892)
177. Gehrig SM, Ryall JG, Schertzer JD, et al. Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage. Exp Physiol 2008;93:1190-8
178. Anwer K, Shi M, French MF, et al. Systemic effect of human growth hormone after intramuscular injection of a single dose of a muscle-specific gene medicine. Hum Gene Ther 1998;9:659-70 (Pubitemid 28200622) (Pubitemid 28200622)
179. Alila H, Coleman M, Nitta H, et al. Expression of biologically active human insulin-like growth factor-I following intramuscular injection of a formulated plasmid in rats. Hum Gene Ther 1997;8:1785-95 (Pubitemid 27488928) (Pubitemid 27488928)
180. Blaschuk OW, Devemy E. Cadherins as novel targets for anti-cancer therapy. Eur J Pharmacol 2009;625:195-8
181. Burden-Gulley SM, Gates TJ, Craig SE, et al. Novel peptide mimetic small molecules of the HAV motif in N-cadherin inhibit N-cadherin-mediated neurite outgrowth and cell adhesion. Peptides 2009;30:2380-7
182. Burden-Gulley SM, Gates TJ, Craig SE, et al. Stimulation of N-cadherin-dependent neurite outgrowth by small molecule peptide mimetic agonists of the N-cadherin HAV motif. Peptides 2010;31:842-9
183. Hatoko M, Niitsuma K, Tanaka A, et al. Expression of N-cadherin and alphaN-catenin in the degeneration/regeneration process of rat skeletal muscle after nerve injury. J Reconstr Microsurg 2004;20:267-73 (Pubitemid 38481139) (Pubitemid 38481139)
184. Cao Y. Monotherapy versus combination therapy of angiogenic and arteriogenic factors for the treatment of ischemic disorders. Curr Mol Med 2009;9:967-72
185. Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003;9:604-13 (Pubitemid 36597108) (Pubitemid 36597108)
186. Li J, Wei Y, Liu K, et al. Synergistic effects of FGF-2 and PDGF-BB on angiogenesis and muscle regeneration in rabbit hindlimb ischemia model. Microvasc Res 2010;80:10-7
187. Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 2004;63:208-16 (Pubitemid 38900835) (Pubitemid 38900835)
188. Binbrek AS, Mittal B, Rao KN, et al. The potential of erythropoietin for conferring cardioprotection complementing reperfusion. Coron Artery Dis 2007;18:583-5 (Pubitemid 47556392) (Pubitemid 47556392)
189. Tamareille S, Ghaboura N, Treguer F, et al. Myocardial reperfusion injury management: erythropoietin compared with postconditioning. Am J Physiol Heart Circ Physiol 2009;297:H2035-43
190. Rezaeian F, Wettstein R, Egger JF, et al. Erythropoietin-induced upregulation of endothelial nitric oxide synthase but not vascular endothelial growth factor prevents musculocutaneous tissue from ischemic damage. Lab Invest 2010;90:40-51
191. Rotter R, Menshykova M, Winkler T, et al. Erythropoietin improves functional and histological recovery of traumatized skeletal muscle tissue. J Orthop Res 2008;26:1618-26
192. Conrad MF, Stone DH, Albadawi H, et al. Local inflammatory and thrombotic responses differ in a murine model of partial and complete hindlimb ischemia/reperfusion. Surgery 2005;138:75-81
193. Hoffmann JN, Vollmar B, Inthorn D, et al. The thrombin antagonist hirudin fails to inhibit endotoxin-induced leukocyte/endothelial cell interaction and microvascular perfusion failure. Shock 2000;14:528-34
194. Hoffmann JN, Vollmar B, Laschke MW, et al. Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition. Crit Care 2005;9(Suppl 4):S33-7 (Pubitemid 41498530) (Pubitemid 41498530)
195. Radley HG, De Luca A, Lynch GS, et al. Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions. Int J Biochem Cell Biol 2007;39:469-77 (Pubitemid 46096791) (Pubitemid 46096791)
196. Strem BM, Hicok KC, Zhu M, et al. Multipotential differentiation of adipose tissue-derived stem cells. Keio J Med 2005;54:132-41 (Pubitemid 41542713) (Pubitemid 41542713)
197. Daniels E. Cytori therapeutics, Inc. Regen Med 2007;2:317-20
198. Fraser JK, Zhu M, Wulur I, et al. Adipose-derived stem cells. Methods Mol Biol 2008;449:59-67
199. Fraser JK, Wulur I, Alfonso Z, et al. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol 2006;24:150-4
200. Zhu M, Kohan E, Bradley J, et al. The effect of age on osteogenic, adipogenic and proliferative potential of female adipose-derived stem cells. J Tissue Eng Regen Med 2009;3:290-301
201. Mizuno H. The potential for treatment of skeletal muscle disorders with adipose-derived stem cells. Curr Stem Cell Res Ther 2010;5:133-6
202. Goudenege S, Pisani DF, Wdziekonski B, et al. Enhancement of myogenic and muscle repair capacities of human adipose-derived stem cells with forced expression of MyoD. Mol Ther 2009;17:1064-72
203. Liu Y, Yan X, Sun Z, et al. Flk-1+ adipose-derived mesenchymal stem cells differentiate into skeletal muscle satellite cells and ameliorate muscular dystrophy in mdx mice. Stem Cells Dev 2007;16:695-706 (Pubitemid 350125220) (Pubitemid 350125220)
204. Schuster MD, Kocher AA, Seki T, et al. Myocardial neovascularization by bone marrow angioblasts results in cardiomyocyte regeneration. Am J Physiol Heart Circ Physiol 2004;287:H525-32 (Pubitemid 38955280)
205. Martens TP, See F, Schuster MD, et al. Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. Nat Clin Pract Cardiovasc Med 2006;3(Suppl 1):S18-22
206. Dixon JA, Gorman RC, Stroud RE, et al. Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation 2009;120(11 Suppl):S220-9
207. Keler T, He L, Ramakrishna V, et al. Antibody-targeted vaccines. Oncogene 2007;26:3758-67 (Pubitemid 46842710) (Pubitemid 46842710)
208. Deasy BM, Qu-Peterson Z, Greenberger JS, et al. Mechanisms of muscle stem cell expansion with cytokines. Stem Cells 2002;20:50-60 (Pubitemid 34118910) (Pubitemid 34118910)
209. Takenaka H, Horiba M, Ishiguro H, et al. Midkine prevents ventricular remodeling and improves long-term survival after myocardial infarction. Am J Physiol Heart Circ Physiol 2009;296:H462-9
210. Sumida A, Horiba M, Ishiguro H, et al. Midkine gene transfer after myocardial infarction in rats prevents remodelling and ameliorates cardiac dysfunction. Cardiovasc Res 2010;86:113-21
211. Sakakima H, Kamizono T, Matsuda F, et al. Midkine and its receptor in regenerating rat skeletal muscle after bupivacaine injection. Acta Histochem 2006;108:357-64 (Pubitemid 44584342) (Pubitemid 44584342)
212. Hu J, Higuchi I, Yoshida Y, et al. Expression of midkine in regenerating skeletal muscle fibers and cultured myoblasts of human skeletal muscle. Eur Neurol 2002;47:20-5